[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Akero Therapeutics, Inc. Common Stock (AKRO)
Novo Nordisk has officially completed its acquisition of Akero Therapeutics for $XX per share plus a $X CVR, totaling up to $XXX billion. This deal could redefine the global obesity and metabolic disease landscape.
About Akero Therapeutics, Inc. Common Stock
Akero Therapeutics, Inc. Common Stock (AKRO) is a biotechnology company focused on developing treatments for serious metabolic diseases.
Akero Therapeutics, Inc. Common Stock uses the ticker $AKRO for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Akero Therapeutics, Inc. Common Stock (AKRO) social dominance hit XXXXXX which is XXX% higher than it's daily average.
- Akero Therapeutics, Inc. Common Stock (AKRO) social dominance is up 2000% from the previous X months.
- Akero Therapeutics, Inc. Common Stock (AKRO) Galaxy Score™ is up XXXXX% from the previous week.
- Akero Therapeutics, Inc. Common Stock (AKRO) creators is up XXXXX% from the previous week.
- Akero Therapeutics, Inc. Common Stock (AKRO) engagements is up 5095.17% from the previous week.
- Akero Therapeutics, Inc. Common Stock (AKRO) mentions is up XXXXX% from the previous week.
- Akero Therapeutics, Inc. Common Stock (AKRO) posts created is up XXXXXX% from the previous week.
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The price of AKRO is likely influenced by the acquisition news from Novo Nordisk, with upfront payments and potential additional shares signaling strong investor confidence and a positive outlook for the company's lead drug.
1-Year High: $XXXXX on 2025-02-05
1-Year Low: $XXXXX on 2025-01-14
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
Akero Therapeutics, Inc. Common Stock (AKRO) is currently AltRank #1,302 based on combined combined social and market metrics
Daily Average: XXXXX
X Week: XXXXX -XXX
X Month: XXXXX +519
X Months: XXXXX -XXX
X Year: XXXXX -XXX
1-Year High: XXXXX on 2025-09-17
1-Year Low: XX on 2025-10-09
Galaxy Score: XX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XX +7
X Month: XX -XX
X Months: XX -XX
X Year: XX -XX
1-Year High: XXX on 2025-05-29
1-Year Low: XX on 2025-11-06
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXXXXX +5,095%
X Month: XXXXXX -XX%
X Months: XXXXXXX +5,166%
X Year: XXXXXXX +2,380%
1-Year High: XXXXXX on 2025-11-13
1-Year Low: X on 2024-12-15
Engagements by network (24h): Reddit: XXX TikTok: X X: XXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: X
X Week: XX +313%
X Month: XX -XX%
X Months: XXX +403%
X Year: XXX +1,176%
1-Year High: XX on 2025-10-20
1-Year Low: X on 2024-12-15
Mentions by network (24h): Reddit: XX TikTok: X X: XX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Akero Therapeutics, Inc. Common Stock (AKRO) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: X
X Week: XX +288%
X Month: XX -XX%
X Months: XXX +875%
X Year: XXX +1,744%
1-Year High: XX on 2025-10-20
1-Year Low: X on 2024-12-15
The most influential creators that mention Akero Therapeutics, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @investseekers | X | XXXXX | X | XX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Month: XXX% no change
X Months: XXX% +33%
1-Year High: XXX% on 2025-02-23
1-Year Low: XX% on 2025-02-09
Most Supportive Themes:
- Increased Social Engagement: (70%) Akero Therapeutics (AKRO) has seen a significant surge in social media activity, with engagements up by 3763.5% over the last X months and posts created up by XX% in the past week.
- Positive Social Dominance Trend: (20%) Social dominance for AKRO has increased by XXXXX% from the previous week, indicating a growing share of online conversation.
- Rising Galaxy Score: (10%) The Galaxy Score™ for AKRO has risen by XXXXX% from the previous week, suggesting improved overall social and market metrics.
Most Critical Themes:
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXXXXX%
X Week: XXXXXXX% +0.00231%
X Month: XXXXXX% +0.0021%
X Months: XXXXXX% +0.004%
X Year: XXXXXX% +0.0036%
1-Year High: XXXXXX% on 2025-10-20
1-Year Low: XXXXXX% on 2025-06-17
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXXXX% on 2025-03-12
1-Year Low: XXXXXXX% on 2025-01-14
Market Cap: $
Market Cap 24-Hour Time-Series Raw Data
Current Value: $
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$0.29%
X Month: $XXXXXXXXXXXXX +$0.84%
X Months: $XXXXXXXXXXXXX +$1.20%
X Year: $XXXXXXXXXXXXX +$123%
1-Year High: $XXXXXXXXXXXXX on 2025-12-03
1-Year Low: $XXXXXXXXXXXXX on 2025-01-14
Top Akero Therapeutics, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$NVO The recent acquisition of Akero Therapeutics further strengthens the company's presence in emerging indications such as non-alcoholic fatty liver disease. #Stocks #Trading #Investment #MarketAnalysis"
X Link @xlalimyqueenx 2025-12-12T14:36Z 1585 followers, XX engagements
"Liver Fibrosis Market Expected to Gain Momentum Through 2034 According to DelveInsight Madrigal Pharma Akero Therapeutics Sagimet Biosciences Boehringer Ingelheim Zealand Pharma #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech"
X Link @ABNewswire 2025-12-11T17:23Z 1657 followers, XX engagements
"Liver Fibrosis Market Expected to Gain Momentum Through 2034 According to DelveInsight Madrigal Pharma Akero Therapeutics Sagimet Biosciences Boehringer Ingelheim Zealand Pharma 89bio"
X Link @newjerseyheadli 2025-12-11T16:01Z XXX followers, XX engagements
"🚨 Novo closed Akero - my thoughts. The News Novo Nordisk ( $NVO) completed the purchase of Akero Therapeutics paying $XX per share in cash plus a non-transferable $X CVR tied to US approval of efruxifermin for compensated cirrhosis due to MASH. Akero is now a wholly owned subsidiary and its stock will be delisted from Nasdaq. The CVR pays only if full US approval is secured by June XX 2031. Efruxifermin is an FGF21 analogue now in Phase X across the SYNCHRONY program. The Phase 2b HARMONY and SYMMETRY trials reported meaningful fibrosis improvements including regression signals even in F4"
X Link @HatedMoats 2025-12-10T19:24Z 9050 followers, 7286 engagements